Bone-sparing Chemoradiotherapy for Anal Cancer - DACG-II
NCT ID: NCT05385250
Last Updated: 2024-08-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
100 participants
INTERVENTIONAL
2021-08-23
2026-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Shared Decision Making With Anal Cancer Patients on Radiation Dose
NCT02785263
Preoperative Radiochemotherapy With Hyperthermia for Locally Advanced Rectal Cancer
NCT02353858
Chemo-radiotherapy as Main Treatment Strategy for Rectal Cancer. Can we Provide a More Precise and Effective Treatment
NCT03619668
Organ Preservation in Locally Advanced Rectal Cancer by Radiochemotherapy Followed by Consolidation Chemotherapy.
NCT03561142
ART: Anal Squamous Cell Carcinoma: Investigation of Functional Imaging During chemoRadioTherapy
NCT02145416
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bone sparring radiotherapy
Observational arm of bone-sparing radiotherapy
Bone sparring radiotherapy
Observation of late side effects from the pelvic bones after bone-sparring radiotherapy for anal cancer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bone sparring radiotherapy
Observation of late side effects from the pelvic bones after bone-sparring radiotherapy for anal cancer
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Indication for standard (chemo)-radiotherapy with curative intend for anal cancer as per multidisciplinary team decision
* Clinical eligible for standard (chemo)-radiotherapy as per physicians' decision
* Written and oral consent
* Age at least 18 years
Exclusion Criteria
* Previous systemic therapy with severe bone marrow suppression or hematological diseases
* Hip-replacements
* Contraindications to MRI-scan
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Herlev Hospital
OTHER
Zealand University Hospital
OTHER
Vejle Hospital
OTHER
Karen-Lise Garm Spindler
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Karen-Lise Garm Spindler
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Karen-Lise G Spindler, DMSc, PhD
Role: STUDY_CHAIR
Experimental Clinical Oncology, AUH, And Danish Anal Cancer Group, DACG
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aarhus University Hospital
Aarhus, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DACG-II
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.